Throughout the projection period, market growth would be driven by the rising incidence of valvular heart disease and an increase in healthcare spending. The high cost of transcatheter heart valve devices, as well as product recalls, are projected to impede the growth of the worldwide prosthetic heart valves market. The growing elderly population, sedentary lifestyle, and technical improvement in prosthetic heart valves are projected to fuel the growth of the worldwide prosthetic heart valves market. Also, the prevalence of rheumatic heart disease has increased. Throughout the projected period, the most prevalent valvular heart condition is predicted to bring profitable growth to the worldwide prosthetic heart valves market.
According to Coherent Market Insights, the global Prosthetic Heart Valves Market is estimated to be valued at US$ 10,307.1 million in 2022 and is expected to exhibit a CAGR of 9.9 % during the forecast period (2022-2030).
Key Leaders in the Prosthetic Heart Valves Industry:
1. Medtronic plc.
Medtronic Navigation, Inc. provides integrated navigation and intra-operative imaging solutions. The company was founded in 1995, headquartered in Colorado, U.S.
2. Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
3. Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
4. LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
5. CryoLife, Inc.
CryoLife is a biological medical device company, which has been focused on the development of implantable biological. In October of 2010, the Company began distributing PerClot for Starch Medical, Inc. (SMI). In May 2011, it acquired Cardiogenesis Corporation. The company was founded in 1984, headquartered in Georgia, U.S.
6. Braile Biomedica
Biomedical Braille company develops and manufactures products in the Cardiovascular, Biological, Electromedical, Endovascular, Transcatheter, and Oncology lines, fruits of the aggregate technology applied to other areas of Medicine, with an institutional mission to develop innovative technologies that reduce the global cost of health and are accessible to the population with the main purpose of caring for people. The company was founded in 1977, headqurtered in Sao Paulo, Brazil.
7. Colibri Heart Valve, LLC
Colibri’s corporate headquarters and pre-commercialization facilities are located in Broomfield, Colorado with R&D located in Houston, Texas. Colibri technology is protected by both trade secrets and issued and pending patent applications with priority claims and content dating back to January 4, 2002. The company was founded in 2010.
8. JenaValve Technology, Inc
JenaValve Technology, Inc. is a medical device company focused on the design, development, and commercialization of innovative transcatheter heart valve solutions for the treatment of patients suffering from heart valve disease. JenaValve is headquartered in Irvine, California, with additional locations in Leeds, U.K., and Munich, Germany. Founded in 2006.
*Definition-Prosthetic heart valves, also known as artificial heart valves, are devices placed in a patient's heart to enhance the function of their heart valves. A mechanical heart valve is the most often utilised prosthetic heart valve for the treatment of valvular heart disease patients.
